Ondine Biomedical Inc.
("Ondine Biomedical", "Ondine" or the "Company")
Posting of Annual Report for the Year Ended 31 December 2021
Ondine Biomedical Inc. (AIM: OBI) announces that its Annual Report for the Year Ended 31 December 2021 was posted on 7th June 2022 and is available on the Ondine website at: https://ondinebio.com/investors/reports-documentation/
**ENDS**
About Ondine Biomedical Inc.
Ondine Biomedical Inc. (AIM: OBI) is a Canadian headquartered, medical device company led by founder and CEO, Carolyn Cross. Ondine has developed a patented, painless, photodisinfection technology platform used in treatment and prevention therapies for a broad-spectrum of pathogens - including multidrug-resistant strains. Photodisinfection is a targeted antimicrobial which uses non-thermal light to activate a photosensitive agent. In a few minutes, this light-based therapy destroys the pathogens' cell membranes and surface proteins through an oxidative burst without impact on human tissue.
Ondine has a pipeline of products, based on its patent protected photodisinfection platform, in various stages of development. Products include treatment of chronic rhinosinusitis, decolonisation of infections in burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and most recently, the development of topical antiviral therapy for the upper respiratory tract to reduce viral titres and transmission of respiratory viruses (e.g., SARS-CoV-2, influenza, RSV, etc.). Ondine's technology is approved in a number of jurisdictions and has been awarded the CE mark, as well as Qualified Infectious Disease Product and Fast Track status in the U.S. by the FDA.
For more information, please visit: www.ondinebio.com or contact:
Ondine Biomedical Inc. |
|
Carolyn Cross, CEO |
+001 (1) 604 669 0555 |
|
|
Strand Hanson Limited (Nominated and Financial Adviser) |
|
James Harris, James Dance |
+44 (0) 20 7409 3494 |
|
|
Arden Partners plc (Broker) |
|
Ruari McGirr, Antonio Bossi |
+44 (0) 20 7614 5900 |
|
|
Vane Percy & Roberts (Media Contact) |
|
Simon Vane Percy, Amanda Bernard |
+44 (0) 77 1000 5910 |